Publications by authors named "M Wakiya"
Herein, we report a regiodivergent desymmetrization of -4,5-epoxycyclohex-1-ene, which results in the formation of two enantioenriched structural isomers with high enantioselectivity from a single compound using a single chiral catalyst.
View Article and Find Full Text PDFArticle Synopsis
- Phyllodes tumors of the breast are classified into benign, borderline, or malignant based on criteria set by the WHO, focusing on factors like stromal cell characteristics and mitotic count.
- A study evaluated various proliferation markers, including Ki-67 and mitotic count, across 76 phyllodes tumors to determine which marker is most effective in distinguishing between tumor types.
- Results indicated that mitotic count was the most reliable marker for differentiating malignant tumors from benign or borderline ones, while other criteria are also important for distinguishing between benign and borderline tumors.
Giant cell arteritis (GCA) is closely associated with polymyalgia rheumatica (PMR). We herein report an 82-year-old woman who developed GCA during PMR treatment. She initially presented with shoulder pain and was diagnosed with PMR based on elevated serum C-reactive protein (CRP) levels and bursitis detected in both shoulders on ultrasonography (US).
View Article and Find Full Text PDFDevelopment of a myxofibrosarcoma in the breast tissue is extremely rare. Reported here is a case of myxofibrosarcoma found in the left breast tissue of a male in his late fifties. The patient first underwent tumor resection, followed by a left mastectomy with the reconstruction of the vastus lateralis valve.
View Article and Find Full Text PDFBackground: It is important for surgeons to determine whether combined portal vein (PV) resection (PVR) is necessary before surgery. The present study aimed to determine the ability of computed tomography (CT) value along the PV in predicting the necessity for concomitant PVR.
Methods: A total of 107 consecutive patients who underwent pancreaticoduodenectomy (PD) for invasive ductal carcinoma of the pancreatic head at our institute between September 2007 and September 2020 were reviewed retrospectively.